Insitro
PrivateLast Round
Series C
Mar 15, 2021
Est. Valuation
$2.57B
Total Funding Raised
$743M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Insitro is a biotechnology company that leverages machine learning and high-throughput biology to accelerate drug discovery and development.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Insitro Comparables
Compare Insitro with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Valo Health | 91% | |
| Xaira Therapeutics | 91% | |
| Insilico Medicine | 87% |
Insitro Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Mar 15, 2021 | ||||
| Series B | May 26, 2020 | ||||
| Series A | Apr 16, 2019 | ||||
| Series A | May 1, 2018 |
Insitro Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series A, Series C, Series B |
| Human Capital | Series C |
| CPP Investments | Series B, Series C |
| SoftBank Investment Advisers | Series C |
| Temasek | Series C |
| GV | Series A, Series B, Series C |
| ARCH Venture Partners | Series B, Series C, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2026
Monthly visitors increased 59% MoM.
- Mar 23, 2026
$10 million received from Bristol Myers Squibb collaboration.
Recent news
Latest coverage and updates
- is_developingOct 15, 2026
Insitro is developing treatments for difficult to treat liver and heart conditions with AstraZeneca in United Kingdom on Oct 15th '26, using its Virtual Human AI platform to identify causal disease biology and advance AstraZeneca-nominated targets from discovery to development-candidate stage.
- hiresSep 8, 2026
Insitro hired Hideo Makimura as Chief Medical Officer on Sep 14th '26.
Insitro Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Insitro's valuation, stock price, and market status.
Is Insitro a public or private company?
Insitro is a private company.
What is the current stock price of Insitro?
Insitro is a private company, so its shares have no public market price. Caplight tracks Insitro's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Insitro worth (valuation)?
Insitro's valuation is estimated at $2.6B based on funding round data.
Can I buy Insitro stock?
Insitro shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Insitro's last funding round?
Insitro's most recent funding round was Series C on March 15, 2021.
Who are the main investors in Insitro?
Key investors in Insitro include Andreessen Horowitz, CPP Investments, ARCH Venture Partners.
Will Insitro IPO soon?
No public IPO plans have been announced for Insitro.
How can I track Insitro secondary market activity?
Caplight tracks bids, offers, and trades in Insitro's shares on secondary markets.